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ABSTRACT
In addition to its role in the prevention of neural tube defects,
folic acid has many other physiological functions, including cell
proliferation, DNA replication, and antioxidant protection. The
aim of this study was to determine the role that folic acid has in
regulating placental trophoblast development. Placental ex-
plants from placentae at gestational age 7 wk (n ¼ 3) were
cultured in folic acid at concentrations of 106 M, 108 M, and
1010 M. Extravillous trophoblast (EVT) invasion was assessed
following 6-day culture, and explants were used for immuno-
histochemical evaluation of proliferation (MKI67) and apoptosis
(active caspase 3). In addition, an array was performed on cell
culture supernatants to examine a range of matrix metal-
loproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs).
Folic acid increased the invasion of EVT cells in this explant
model by between 83% and 19% (P ¼ 0.005), and this was
associated with increased MKI67 positivity and decreased active
caspase 3 positivity; this effect was concentration dependent and
showed a biphasic response. In addition, culture in folic acid
increased vascular density, as determined by anti-CD31 immu-
nostaining (P ¼ 0.05). The increase in EVT invasion correlated
with increased placental explant secretion of MMP2 (P¼ 0.01),
MMP3 (P¼0.01), and MMP9 (P¼0.02). This study demonstrates
that folic acid is potentially important in a number of crucial
early stages of placental development, including EVT invasion,
angiogenesis, and secretion of MMPs, and highlights the need for
further studies to address the benefit of longer-term folic acid
supplementation throughout pregnancy to prevent pregnancy
disorders associated with deficient placental development,
including preeclampsia.
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INTRODUCTION
Folic acid, the synthetic form of folate, is involved in a
number of important functions within the body, including
synthesis of proteins required for DNA replication and as an
essential substrate for a range of enzymatic reactions needed
for amino acid synthesis and vitamin metabolism; as such, folic
acid is essential for cell multiplication and differentiation
processes [1, 2]. With regard to pregnancy, the importance of
folic acid in the prevention of neural tube defects has long been
known [3]. However, folic acid may also have important roles
in other physiological pathways needed for successful
pregnancy, including angiogenesis and vasculogenesis [4],
methylation of the harmful, sulphur-containing homocysteine
[5], antioxidant protection [6], and endothelial-dependent
vascular relaxation [7]. These processes are essential for the
establishment of fetoplacental circulation, enabling successful
pregnancy outcome.
Placentation requires the invasion of fetally derived
extravillous trophoblast (EVT) cells into maternal uterine
spiral arteries, converting these arteries from highly resistant
low-capacity vessels into a high-capacity system capable of
transporting large volumes of blood to the intervillous space
[8]. This process of EVT invasion requires the degradation and
remodeling of the extracellular matrix, which is performed
mainly by matrix metalloproteinases (MMPs) [9], whose
function and substrate specificity is regulated by their specific
inhibitors, tissue inhibitors of MMPs (TIMPs) [10]. Between 8
and 12 wk of pregnancy, trophoblast plugs that have
accumulated in the spiral arteries are released, allowing the
complete perfusion of the syncytiotrophoblast with maternal
blood and the establishment of hemotrophic nutrition [11, 12].
The sudden perfusion of placental villi at the onset of maternal-
placental circulation has been associated with the generation of
oxidative stress, although the placenta is protected from undue
harm by a number of antioxidant enzymes [13, 14]. Folic acid
also has antioxidant activity and is directly able to scavenge
free radicals and also increase the bioavailability of nitric oxide
[15, 16].
In parallel to gaining access to the maternal circulation, the
placenta must also develop its own circulation. Endothelial
cells differentiate from mesenchymal cells, forming the first
capillaries of the fetal placental vasculature. This coincides
with maternal vascular remodeling and the onset of maternal
blood flow into the placental intervillous space [17]. Develop-
ment of the placental circulation requires both vasculogenesis,
the development of new blood vessels from primitive precursor
cells, and angiogenesis, which is the development of new
vessels from a preexisting vasculature [18]. Placental angio-
genesis is critical for development of a normal placental
circulation and, consequently, normal development of the baby
[19]. Folic acid is able to induce angiogenesis, in part via a
nitric oxide-dependent mechanism [4].
Maternal folic acid deficiency has been associated with
miscarriage [20], placental abruption, and intrauterine growth
restriction [21]. Low folate levels have also been found in
plasma samples from women with preeclampsia [22]. Increas-
ing folic acid intake and prolonging the period of folic acid
supplementation from the currently recommended first 12 wk
of pregnancy to throughout the length of gestation may serve to
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help prevent preeclampsia by allowing optimal placental
development. A recent study has shown the beneficial effect
of extending folic acid supplementation into the second
trimester of pregnancy, with a reduced incidence of preeclamp-
sia [23]. Longer-term folic acid supplementation during
pregnancy may also help ameliorate the secondary systemic
symptoms of preeclampsia because of its beneficial effects on
endothelial function and antioxidant protection.
We hypothesized that folic acid would increase both
invasion by EVT cells and angiogenesis in placental explants
from early pregnancy.
MATERIALS AND METHODS
After local ethics committee approval and with appropriate informed
consent, placental tissue was obtained from women undergoing elective
surgical termination of pregnancy at 7 wk gestational age calculated from
ultrasound measurement of crown-rump length. Placental tissue was identified
by its branching, fronded appearance.
Invasion Assays
The effect of folic acid on the ability of EVTs from placental explants (7 wk
gestational age) to invade through Matrigel growth factor-reduced basement
membrane (BD, supplied by VWR, Lutterworth, U.K.) was assessed as
described previously [24]. Briefly, chorionic villous tips were minced to
approximately 0.5 mm3 and resuspended in culture medium (Dulbecco
modified Eagle medium (DMEM):F12 [Biosource, Camarillo, CA] containing
10% fetal bovine serum, penicillin/streptomycin, and amphotericin B [all from
Sigma Aldrich, Dorset, U.K.]). Dissected placental tissue was resuspended in
500 ll of culture media such that 15 ll constituted approximately 10 mg of
tissue. Using a pipette, 15 ll of placental tissue explant suspension was drawn
up and carefully spread onto the surface of the Matrigel-coated cell culture
insert. To assess the effect of folic acid on EVT invasion, exogenous folic acid
(106 M, 108 M, or 1010 M) was added to the culture media; these
concentrations were chosen because they represent physiological ranges [25].
Each experiment was performed in duplicate and performed on three separate
placentae. Assays were incubated in standard tissue culture conditions of 378C,
5% CO
2
(20% O
2
) in an air incubator. At the end of the 6-day incubation
period, the Matrigel and filters were removed, and the upper side of the
membrane was cleaned using a cotton wool bud. For assessment of invaded
cells, the filters were stained with hematoxylin and eosin and mounted on glass
microscope slides with aqueous mountant. Each slide was blinded, and the total
number of cells that had invaded to the underside of the filter was counted by
P.J.W. at 1003magnification for the entire area of the filter. To account for the
considerable variation between different placental samples, mean cell counts
for each invasion assay with explants from a single placenta were normalized
with respect to the control values for that experiment.
To determine whether folic acid altered trophoblast cell viability and
numbers (apoptosis and proliferation), at the end of the invasion assay, explants
were removed and fixed in 10% neutral-buffered formalin for 24 h and
processed into paraffin wax. Serial 3-lm sections were immunolabeled using a
standard avidin-biotin peroxidase method (Vector Laboratories, Peterborough,
U.K.) with rabbit anti-active caspase 3 (pretreatment citrate buffer, pH 6.0, with
10-min microwave heating, 1:400 dilution for 45 min; R&D Systems,
Abingdon, U.K.), mouse anti-MKI67 (pretreatment pressure cooking for 1
min in citrate buffer, pH 6.0, 1:200 dilution for 30 min; Novocastra
Laboratories, Newcastle-upon-Tyne, U.K.), and anti-CD31 (pretreatment
pressure cooking for 1 min in citrate buffer, pH 6.0, 1:20 dilution for 60
min; Novocastra Laboratories). CD31 labeling was used as a marker of
angiogenesis [26]. In addition, conditioned medium was collected from each
chamber and stored at 808C until required for analysis.
Protease Array
Concentrations of MMP1, MMP2, MMP3, MMP7, MMP8, MMP9,
MMP10, MMP12, MMP13, TIMP1, TIMP2, and TIMP4 were assayed in
conditioned media collected following 6-day explant culture, using the
ExcelArray Human MMP/TIMP array kit per the manufacturer’s instructions
(Thermo Fisher Scientific, Loughborough, U.K.) and as described previously
[27]. Multiplex standards were prepared per instructions in the ranges of 123 to
10 000 pg/ml (MMPs 1, 3, 7, 8, 9, 10, 12, and 13, and TIMP4) and 309 to
25 000 pg/ml (MMP2, TIMP1, and TIMP2). A total of 100 ll of cell culture
supernatant was assayed. Samples and controls were assayed in triplicate. The
microarray slide was imaged using an Axon GenePix 4200AL slide scanner
(MDS Analytical Technologies, Wokingham, U.K.), and spot densitometry was
performed using GenePix 2.0 software. The spot densitometry data generated
was imported into Microsoft Excel.
Quantification of Immunohistochemistry
Quantification of MKI67, active caspase 3, and CD31 immunostaining was
performed using the Positive Pixel Algorithm of Aperio ImageScope software
(Oxford, U.K.). This software is able to discriminate between positively and
negatively stained pixels, and combines the number of positive pixels stained
with the intensity of staining of these same pixels to produce the value
‘‘positivity.’’ Analysis of the entire placental explant was performed for all
assays. For each folic acid concentration, slides were counted from the
duplicate wells (i.e., a total of six slides were counted for each concentration for
the three assays performed). Analysis was performed at 2003magnification by
P.J.W., who was blinded to sample identity.
Statistical Analysis
All analyses were performed using SPSS for Windows version 16.0
(Chicago, IL). The Kolmogorov-Smirnov test was used to assess the
distribution of data. All data were found to be normally distributed, and
therefore between-group comparisons were made using one-way ANOVA; if
significant, they were followed by the Bonferroni post hoc test. Concentration
response effects for invasion assays were determined using Kendall s B test. A
value of P ¼ 0.05 was considered significant for invasion assays and
immunohistochemistry. Unless otherwise stated, all data are expressed as mean
(SEM).
RESULTS
Folic Acid Increases EVT Invasion
Culture in folic acid produced a concentration-dependent
increase in the mean invasion index of EVT (Fig. 1). When
compared with control wells, incubation with folic acid at
concentrations of 106 M increased invasion by 83% (P ,
0.0001), at 108 M by 51% (P , 0.0001), and at 1010 M by
19% (P ¼ 0.01). Kendall s B test showed this increased EVT
invasion to be concentration dependent (P ¼ 0.005; Fig. 1).
Trophoblast Cell Apoptosis and Proliferation Following
Culture in Folic Acid
As shown in Figure 2a, placental explant culture in folic
acid at 106 M resulted in increased active caspase 3 positivity
compared with controls, with staining predominantly observed
in villous cytotrophoblast and villous stromal cells (P¼ 0.028).
In contrast, active caspase 3 positivity decreased when
FIG. 1. Effect of culture in folic acid at 106 M, 108 M, and 1010 M
concentrations on the invasive capacity of placental villous explants. Data
are expressed as mean normalized to DMEM:F12 control 6 SEM.
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compared with controls cultured in folic acid at concentrations
of 108 M (P ¼ 0.001) and at 1010 M (P ¼ 0.024).
MKI67-positive staining was mainly found in the villous
cytotrophoblast of placental explants. When compared with
controls, MKI67 positivity was reduced in placental explants
following culture in 106 M folic acid (P ¼ 0.012). However,
culture in folic acid at 108 M produced an increase in MKI67
positivity compared with controls (P ¼ 0.001), and this
increased MKI67 positivity was also found following culture
with folic acid at 1010 M (P ¼ 0.039 vs. control; Fig. 2b).
Alteration in CD31 Staining Following Culture with
Folic Acid
Vascular density, as determined by CD31 immunostaining,
increased following culture with folic acid (Fig. 3a). When
compared with controls, CD31 positivity in placental explants
was higher following culture with folic acid at concentrations
of 106 M (P¼ 0.001), 108 M (P¼ 0.002), and 1010 M (P¼
0.02). Furthermore, the increased CD31 expression following
culture with folic acid was found to be a concentration-
dependent response (P ¼ 0.05; Fig. 3b).
Variation in MMP/TIMP Secretion Following Culture with
Folic Acid
Standard curves generated for all analytes had R2 values of
0.97 or above. Coefficients of variation for triplicate repeats
were all less than 10%. Detectable levels of MMP2, MMP3,
MMP7, MMP8, MMP9, MMP10, MMP12, MMP13, TIMP1,
TIMP2, and TIMP4 were found in placental explant culture
supernatants after incubation of 6 days in folic acid at 106 M,
108 M, and 1010 M concentrations (Fig. 4).
The concentration of MMP2 secreted by placental explants
increased following treatment with folic acid at 106 M, 108
M, and 1010 M in a concentration-responsive manner (P ¼
0.01). The greatest effect on MMP secretion following culture
with folic acid was seen for MMP3, which showed a
concentration-responsive increase (P ¼ 0.01) in secretion by
placental explants following culture in folic acid at concentra-
tions of 106 M, 108 M, and 1010 M. MMP9 secretion was
also increased in a concentration-dependent manner after
culture in folic acid at concentrations of 106 M, 108 M,
and 1010 M (P ¼ 0.02).
Levels of MMP1 fell below the range of detection of the
ExcelArray kit. Concentrations did not vary between controls
FIG. 2. Effect of culture in folic acid at
concentrations of 106 M, 108 M, and
1010 M on (a) caspase 3 expression and (b)
MKI67 expression of placental villous ex-
plants. Data are shown as mean positivity6
SEM. Original magnification 3200.
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and those treated with folic acid for MMP7, MMP8, MMP10,
MMP12, MMP13, TIMP1, TIMP2, and TIMP4.
DISCUSSION
This study demonstrates for the first time that folic acid, at
low concentrations, is able to increase EVT invasion and
placental secretion of MMP2, MMP3, and MMP9. Addition-
ally, folic acid displays a biphasic effect on placental explant
proliferation and apoptosis in early pregnancy.
Folic acid may have a key role in regulation of EVT
invasion, which is a crucial part of placental development.
Invasion of EVT into the maternal decidua and inner third of
the myometrium is crucial for the remodeling/transformation/
conversion of the maternal spiral arteries, allowing the
establishment of uteroplacental circulation [28]. Inadequate
EVT invasion is associated with defective placental develop-
ment, with a reduction in both the number of remodeled spiral
arteries in decidua and myometrium and in the depth of
remodeling, which is deficient particularly in myometrium; this
is suggested to be the primary defect that occurs in
preeclampsia and intrauterine growth restriction [29]. Supple-
mentation with folic acid during the very early stages of
pregnancy may therefore be beneficial by promoting EVT
invasion, which could be of benefit in preventing pregnancy
disorders associated with inadequate EVT invasion. Indeed, a
recent observational study identified that continuation of folic
acid supplementation into the second trimester of pregnancy
was associated with reduced incidence of preeclampsia [23]
and that exposure to folic acid antagonists increases the risk of
placental abruption, intrauterine growth restriction, and fetal
death [21]. Furthermore, treatment with the antifolate drug
methotrexate in ectopic pregnancy has been shown to reduce
placental growth and EVT invasion due to reduced trophoblast
proliferation, although caution must be used when comparing
ectopic pregnancy and normal placental development [30].
CD31 labeling confirmed that culture with folic acid
increased angiogenesis in placental explants. Placental angio-
genesis is crucial for the appropriate development of the
fetoplacental circulation, thereby maximizing blood flow
throughout the placenta and, correspondingly, the rate of
nutrient and gas exchange between the mother and her baby.
The observed doubling of vascular density following culture
with folic acid also provides a possible explanation for the
reported reduction in vascular density in preeclampsia and
intrauterine growth restriction when supply of folic acid is
limited [21]. Placental explants have previously been used for
the assessment of angiogenesis [31]; however, it is acknowl-
FIG. 3. Effect of culture in 106 M, 108
M, and 1010 M concentrations of folic acid
on vascular density of placental villous
explants, as determined by CD31 immuno-
staining. In photomicrographs (a) CD31-
positive cells appear brown and are clearly
visible around placental vessels (indicated
by arrows). Original magnification3200. In
graphs (b) data are shown as mean positivity
6 SEM.
FIG. 4. Effect of culture in folic acid at
concentrations of 106 M, 108 M, and 10
10 M on secretion of MMPs and TIMPs
from placental explants following 6-day
culture. Data are shown as mean positivity
6 SEM.
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edged that further studies are needed to further delineate the
involvement of folic acid in placental angiogenesis.
The increase in EVT invasion associated with folic acid
supplementation may be explained by the increased production
of MMP2, MMP3, and MMP9. The importance of MMP
activity in trophoblast invasion has been described previously
[32, 33], and their expression has been confirmed in both early
and late pregnancy placental tissue [34, 35]. Increased
production of the gelatinases (MMP2 and MMP9) may be
associated with increased EVT invasion due to increased
degradation of type IV collagen in the basement membrane,
allowing increased numbers of EVT cells to invade through the
maternal decidua. MMP3, also known as stromelysin-1, may
also be involved in the increased invasion of EVT via
degradation of a variety of extracellular matrix components,
including proteoglycans, fibronectin, laminin, and type IV
collagen, and has been shown to be present throughout
pregnancy [36]. Although the assay used does not detect
MMP activity, we suggest that the increased production of
MMP2, MMP3, and MMP9 would also be associated with
increased enzymatic activity of these metalloproteinases,
because folic acid was not found to alter the production of
the TIMPs, which downregulate the activity of MMPs. The use
of zymography to determine the activity of MMP2, MMP3,
and MMP9 would allow a more complete assessment of the
effect of folic acid on MMP activity.
The biphasic concentration-dependent response of varying
concentrations of folic acid on EVT proliferation and apoptosis
(Fig. 2) was unexpected; micromolar concentrations were
associated with increased apoptosis and reduced proliferation,
whereas culture in nanomolar concentrations caused decreased
apoptosis and increased proliferation. This biphasic response
was mirrored between apoptosis and proliferation, suggesting
involvement of a common pathway in these responses. It has
previously been reported that reduced folic acid availability is
associated with increased placental apoptosis [37]. However,
that study used pooled cytotrophoblast samples from term
placentae, 7 mo later in gestation than the tissues reported here.
The response to folic acid may well be different in term tissues
and following the process of parturition and labor. Further-
more, it is known that folic acid stores are depleted during
pregnancy [38], which may alter placental responses. There is
increasing interest in the use of micronutrient and vitamin
supplementation during pregnancy to maximize health benefits
for both mother and baby [39–41]. Despite public health
campaigns recommending the use of preconceptual folic acid
supplementation, the dietary intake of folic acid is still
inadequate in around 13 million people within the United
Kingdom [42]. However, the biphasic nature of the response to
folic acid emphasizes the importance of careful evaluation of
concentration before implementation of supplementation, an
issue that was highlighted in a recent Cochrane review of
micronutrient supplementation in pregnancy [43]. Concentra-
tions higher than the current daily recommendation of 400 lg
may be harmful with regard to placental development. A recent
report showed median serum folate levels to be 23.5 nmol/L
during the first trimester of pregnancy among women who took
400-lg folic acid supplements [44]. In the present study, this
median serum folate concentration falls within the 108 M
treatment group, which increased cell proliferation and
decreased apoptosis of the EVT cells. Extrapolation from
these preliminary data might suggest possible deleterious
effects of very high-dose supplementation, but this is in any
case contraindicated because of the risk of masking the effects
of any vitamin B
12
deficiency. In line with this are the
contrasting reports regarding folic acid supplementation and
cancer treatment. A recent report has highlighted the need to
limit folic acid supplementation to no more than 400 lg, rather
than the 1000 lg more frequently prescribed for cancer patients
to limit tumor cell proliferation [45]. In contrast, Hervouet et al.
[46] have suggested that folate supplementation can act as a
promising adjuvant for antiglioma therapies because of its role
in DNA methylation, as well as increasing apoptosis and
decreasing proliferation.
Possible limitations of the current study are the use of
placental samples from one gestational time point (7 wk).
Nevertheless, the use of placentae from the same time point
allows assessment of the effects of folic acid with fewer
confounding factors, because combining results from placental
samples from a wider range of early pregnancy samples may
lead to misleading interpretation of results, because the
invasive capacity of EVTs during the first 20 wk of pregnancy
has been shown to be different [47]. A further possible
limitation may be the use of placental explants as the source of
EVT, rather than isolating a pure population of EVTs using a
Percoll gradient. Purified EVTs were not used in the present
study because of the relatively low yield of cells obtained using
this method, which would have reduced the number of folic
acid concentrations that could have been assessed in each
experiment. However, previous studies have confirmed the
phenotype of the invaded cells from the placental explants to
be consistent with an EVT population [48]. Future studies
using placental samples from sequential gestational age points
within the first trimester would be useful in determining
whether the effect of folic acid on EVT function observed in
the current study applies to a wider range of gestational ages, or
whether it specific to 7 wk of gestation.
In summary, the current study highlights a further possible
benefit of periconceptual and maintained folic acid supple-
mentation, stimulating increased EVT invasion via increased
secretion of MMP2, MMP3, and MMP9, as well as altered
placental/trophoblast proliferation and apoptosis, and a dou-
bling of vascular density. All of these aspects require further
investigation to allow the potential for longer-term supple-
mentation of folic acid throughout pregnancy as a means of
preventing and/or alleviating symptoms of preeclampsia.
Furthermore, the biphasic response of placental cells to folic
acid emphasizes the need for carefully monitored functional
studies to be performed prior to the implementation of
supplementation trials.
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